After the close of trading on the 28th, the stock hit its daily upward limit, reaching a new high for the year. The company announced that its patent application for a cartilage cell sheet under development in the United States has been approved, which is considered a positive development. The patent is the result of joint research on the same type of cartilage cell sheet conducted by Professor Masato Sato of the Department of Orthopedics, Faculty of Medicine, School of Medicine, Tokai University. The cell sheet for the treatment of degenerative knee joint disease currently under development uses the same type of cartilage cell sheet derived from cartilage tissue collected from patients with polydactyly (a disease where the patient is born with more than 5 fingers or toes) based on the manufacturing method of this patent.
セルシード---年初来高値更新、移植用「軟骨細胞シート」が米国で特許査定
Cellseed- Stock hits year-to-date high, patent assessment for 'cartilage cell sheet' for transplantation in USA.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.